Skip to main content
Clinical Trials/NCT06760377
NCT06760377
Not yet recruiting
Not Applicable

Dietary Supplements for Reduction of Intestinal Permeability Levels

Universidad Complutense de Madrid1 site in 1 country85 target enrollmentFebruary 1, 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Intestinal Permeability
Sponsor
Universidad Complutense de Madrid
Enrollment
85
Locations
1
Primary Endpoint
Zonulin levels in feces
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

A randomised and controlled trial, in which the effect of a dietary supplement is evaluated for reduction of intestinal permeability levels of subjects with high levels of zonulin in feces

Detailed Description

Randomized clinical trial, with masking of the statistician and the evaluator, to assess the effect of a food supplement, composed of substances that promote intestinal mucosa repair, on the levels of zonulin in feces and consequently on intestinal permeability. A control group of subjects not receiving any type of supplementation will be used to compare the effectiveness of the treatment. The main objective of this study is to determine if the use of a dietary supplement composed of glutamine, butyrate and lion's mane, among others, corrects the levels of zonulin in feces.

Registry
clinicaltrials.gov
Start Date
February 1, 2025
End Date
June 1, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Isidro Fernández López

Principal investigator

Universidad Complutense de Madrid

Eligibility Criteria

Inclusion Criteria

  • Subjects between 18 and 65 years of age with elevated levels of zonulin in stool (greater than 80 ng/ml).

Exclusion Criteria

  • Taking any type of antibiotic in the last month
  • Taking prebiotics or probiotics products in the last month.
  • Taking laxatives in the last month.
  • Undergoing any medicinal treatment
  • Pregnancy
  • Subject with a history of current gastrointestinal pathology or disorder such as: acute colon pathology, acute haemorrhagic colitis, suspected digestive perforation, recent abdominal surgery, severe arterial hypertension, abdominal hernia, colon neoplasia, history of cardiac syncope, renal failure, liver cirrhosis, epilepsy, severe psychiatric illness (psychosis), necrosis due to abdominal irradiation, severe anaemia, severe neurovegetative lability.

Outcomes

Primary Outcomes

Zonulin levels in feces

Time Frame: 60 days

Zonulin levels in feces, assessed in ng/ml

Study Sites (1)

Loading locations...

Similar Trials